Let's Talk Risk! Podcast

FDA: There is no reason to restrict the continued use of fluoropolymers in medical devices.
What happens when pressure to eliminate a material creates greater risk for the patient?
This Deep Dive examines the growing regulatory tension around PFAS and medical-device fluoropolymers, and why evaluating substitution requires more than asking whether a material belongs to a broad chemical category.
Key highlights covered in the audio:
* Not all PFAS present the same risk. The discussion distinguishes small-molecule PFAS from large, biostable fluoropolymers such as PTFE and PVDF used in medical devices.
* FDA’s position is supported by extensive clinical experience. Decades of use and a large ECRI review found no conclusive evidence of patient harm from PTFE.
* Substitution can introduce new clinical hazards. Changes in friction, flexibility, chemical resistance, sealing, or coating integrity can directly affect device performance and patient safety.
* This creates a substitution risk paradox. Eliminating one perceived material hazard may introduce more immediate risks such as reduced trackability, altered drug delivery, particulate shedding, or embolic complications.
* The decision belongs inside risk management. Under ISO 14971, the key question is how substitution changes the device’s total risk profile—not simply whether the original material can be removed.
* A defensible strategy requires evidence. Chemical characterization, toxicological assessment, clinical evidence, and post-market surveillance can support continued use of a proven material.
Keywords:
PFAS, Fluoropolymers, PTFE, Medical Devices, FDA, Material Substitution, ISO 14971, Benefit-Risk Assessment, Patient Safety, Risk Management
🎧 Listen to the Deep Dive for a closer look at why eliminating a perceived material hazard does not necessarily reduce the overall risk of a medical device.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026). PFAS in Medical Devices: What You Need to Know, FDA Web Resource, U.S. Food and Drug Administration
* Regulatory Affairs Group (2026). EU PFAS Restriction for Medical Devices: REACH Timelines and Derogations, Strategic Industry Report, MedTech Regulatory Guide


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

Patient preference is no longer a soft qualitative afterthought.
What if a device carries significant risks, but patients are willing to accept them for a meaningful clinical benefit?
This Deep Dive examines how FDA’s evolving approach to Patient Preference Information (PPI) can turn those tradeoffs into quantitative evidence for regulatory benefit-risk decisions.
Key highlights covered in the audio:
* PPI is not the same as a patient-reported outcome. PROs describe what patients experience. PPI asks what risks patients are willing to accept to obtain a particular benefit.
* Risk tolerance can be quantified. Methods such as discrete choice experiments and threshold techniques can establish measures such as Maximum Acceptable Risk (MAR) and help define the level of benefit patients consider meaningful.
* Study design matters enormously. Patient comprehension, health numeracy, neutral presentation of risk, attribute selection, statistical analysis plans, and appropriate visual communication can determine whether preference data are credible.
* FDA engagement needs to happen early. The discussion highlights the importance of using the Q-Submission process to align on attributes, ranges, methodology, and statistical analysis before the study is conducted.
* PPI can extend beyond premarket approval. Preference information may inform labeling, shared decision-making, post-market benefit-risk assessments, and other decisions across the total product lifecycle.
Keywords:
Patient Preference Information, FDA Guidance, Benefit-Risk Assessment, Risk Tolerance, Medical Devices, Discrete Choice Experiment, Maximum Acceptable Risk, Q-Submission, Total Product Lifecycle, Risk Management
🎧 Listen to the Deep Dive for a closer look at how patient preference is becoming part of the quantitative language of medical-device risk management.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026, March 30). Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle, FDA Guidance Document, U.S. Food and Drug Administration
Pure Global (2026, April 8). FDA 2026 Guidance on Voluntary Patient Preference Information, Strategic Industry Report, Pure Global


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

The vulnerability of the modern clinical lab is quite literally concentrated at the point of the needle.
Clinical laboratories have automated almost everything after the blood reaches the tube. Yet one of the most common invasive procedures in healthcare still depends on a person finding a vein by sight and touch and manually inserting a needle.
FDA’s De Novo authorization of Vitestro’s Aletta® may signal that this last major manual bottleneck is beginning to change.
But this Deep Dive is about much more than a robot drawing blood.
It explores a bigger question for anyone working in risk management, quality, regulatory, clinical, or medical-device development.
What does it take to make an autonomous medical device safe enough to perform an invasive clinical procedure on its own?
In this audio brief, we unpack how Aletta combines imaging, robotics, software constraints, clinical supervision, and layered fail-safes — and how FDA evaluated a technology for which no predicate existed before.
The result is a fascinating case study in how risk management changes when a machine begins doing what previously required a trained human.
Key highlights covered in the audio:
* De Novo pathway: De Novo authorization was necessary because there was no existing predicate for autonomous robotic phlebotomy.
* Risk controls built around autonomy: imaging, software constraints, movement detection and supervisory intervention create multiple layers of protection.
* Clinical performance: the ADOPT study reported a 94.5% first-stick success rate when a suitable vein was identified, including strong performance in patients with obesity and difficult venous access.
* Specimen quality: robotically collected samples demonstrated analytical equivalence for the laboratory parameters evaluated.
* Patient acceptance: 90% reported similar or less pain than manual phlebotomy, while 82% preferred the robotic system or had no preference.
* A different workforce model: FDA-authorized use allows one trained phlebotomist to supervise up to three devices simultaneously.
Keywords:
FDA De Novo, Aletta, Vitestro, autonomous medical devices, robotic phlebotomy, artificial intelligence, medical robotics, risk management, clinical evidence, human oversight, diagnostic testing, automation
🎧Click Play above to listen to a brief audio summary about this groundbreaking technology.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* Giesen LFP, Roest JA, et al. (2026, April 14). Performance, Safety, and Patient Experience of an Autonomous Robotic Phlebotomy Device: A Multicenter Trial, Clinical Chemistry (hvag029), Oxford Academic
* FDA (2026, August 19). FDA Authorizes First-Of-Its-Kind Robotic Blood Draw Device, FDA News Release, FDA
* Evidence-Based Medical Insight (2026, August 19). Clinical, Regulatory, and Operational Analysis of the Aletta Autonomous Robotic Phlebotomy System: A New Paradigm in Preanalytical Automation, Evidence-Based Medical Insight
* Bristow, H. (2026, May 27). Robotic Phlebotomy Trial: What the Patients Said, The Pathologist


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

Summary
“I don't think it's as easy to outsource risk as it used to be. Risk is pervasive now.”
In this episode of the Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Allyson Mullen, Director at Hyman, Phelps & McNamara, P.C., about what FDA’s early enforcement activity under the Quality Management System Regulation (QMSR) may tell medical device manufacturers about the agency’s evolving expectations.
Using the first warning letter discussed in the episode as a starting point, Allyson examines how FDA is citing risk management under ISO 13485 Clause 7.1 and, increasingly, looking at the broader requirement to apply risk-based thinking across QMS processes under Clause 4.1.2.
The conversation explores why companies already certified to ISO 13485 should not assume they are fully prepared for an FDA inspection, how FDA inspections may differ from notified-body audits, and why post-market information must feed back into risk management.
Naveen and Allyson also discuss the legal and contractual implications of the transition, particularly the importance of reviewing quality agreements and clearly defining responsibilities when activities are outsourced.
Finally, Allyson offers practical perspective on responding to FDA 483 observations and warning letters during a period when both regulators and industry are adapting to a new inspection framework.
Listen to the full 25-minute podcast or jump to a section of interest listed below.
Chapters
01:17 – Introduction and Allyson Mullen’s Regulatory and Legal Background02:17 – FDA’s First QMSR Warning Letter and Its Risk Management Findings03:46 – How FDA’s Language Around Risk Is Changing Under QMSR05:10 – Risk Beyond Design Control: ISO 13485 Clause 4.1.207:42 – When FDA May Look Beyond Product Realization12:48 – Why ISO 13485 Certification May Not Be Enough14:59 – Legal Risks and the Importance of Updating Quality Agreements17:19 – What to Do When FDA May Have Gotten an Observation Wrong21:21 – Warning Letters and the Challenges of the QMSR Transition23:40 – Allyson’s Journey from Regulatory Affairs to Law26:10 – Key Takeaways: Risk, Outsourcing, and Quality Agreements
If you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.
Suggested links:
FDA Law Blog: FDA’s First QMSR Warning Letters.
LTR Deep Dive: First FDA Warning Letter Under QMSR.
LTR: LTR Risk Coach - AI-Powered Decision Support Tool.
Key Takeaways
* Risk is becoming more pervasive under QMSR. FDA now has clearer regulatory pathways for examining risk beyond traditional design-control activities.
* Clause 7.1 may only be the beginning. Product realization provides an obvious entry point, while ISO 13485 Clause 4.1.2 allows FDA to examine whether risk-based thinking is embedded throughout the QMS.
* Post-market feedback must close the loop. Complaints, adverse events, recalls, and other post-market information need a defined pathway back into risk management.
* ISO 13485 certification does not guarantee an easy FDA inspection. FDA may challenge the methods and reasoning behind risk-based decisions more deeply than organizations have experienced in traditional notified-body audits.
* Risk cannot simply be outsourced. Manufacturers remain responsible for understanding and managing risk even when product-realization activities are performed by suppliers or contract manufacturers.
* Review quality agreements now. Older agreements may assign responsibilities using the former QSR structure and may not adequately address obligations under ISO 13485 and QMSR.
* A 483 is not necessarily the final word. Companies should carefully evaluate FDA observations, provide missing context, correct the record where appropriate, and respond with a complete factual narrative.
* The transition creates challenges for both FDA and industry. Early warning letters and inspection observations will be important signals for understanding how FDA applies QMSR in practice.
Keywords
QMSR, FDA, ISO 13485, Risk Management, Quality Systems, FDA Inspections, Warning Letters, Quality Agreements, Post-Market Surveillance, Medical Devices
About Allyson Mullen
Allyson Mullen is a Director at Hyman, Phelps & McNamara, P.C., where her work brings together deep experience in FDA regulatory matters and law.
Before joining the firm, she served as a Corporate Attorney and Principal Regulatory Affairs Specialist at Waters Corporation, a Senior Regulatory Affairs Specialist at Boston Scientific, and a Regulatory Affairs Associate at DePuy Mitek.
She earned her J.D. from New England Law | Boston and began her career in regulatory affairs before transitioning into legal practice—giving her experience on both sides of regulatory and legal decision-making.
Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.
Disclaimer
Information and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.
Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards.



This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe

Under QMSR, FDA is not only looking for individual quality failures. It is examining how failures connect across the entire quality system.
FDA’s warning letter to Linemaster Switch Corporation provides an early look at QMSR enforcement in practice. The cited deficiencies extend across risk management, rework, corrective action, environmental controls, calibration, and software validation.
The individual expectations are not entirely new. What has changed is the regulatory structure through which FDA evaluates them. By citing specific ISO 13485:2016 clauses, FDA can follow the connections between manufacturing risk, quality data, operational controls, and postmarket feedback rather than treating each deficiency as an isolated compliance issue.
The warning letter also demonstrates how a seemingly simple documentation gap—such as a blank root-cause field—may reveal a much broader failure of investigation, escalation, management oversight, and corrective action.
Key highlights covered in the audio:
* Why risk management must extend beyond the design file and into product realization
* FDA’s citation of a missing process FMEA under ISO 13485 Clause 7.1
* How undocumented rework exposed weaknesses in production control and reevaluation
* Why a blank root-cause field represented a failed corrective-action feedback loop
* How environmental conditions, calibration accuracy, and software validation became interconnected findings
* What earlier warning letters reveal about continuity between QSR and QMSR expectations
* Practical areas QA and RA leaders should reassess in legacy quality-system records
Keywords:
FDA QMSR warning letter, Linemaster Switch Corporation, ISO 13485 enforcement, FDA medical device inspections, QMSR risk management, process FMEA, medical device rework, corrective action, software validation, quality system regulation.
🎧Click Play above to listen to a brief audio summary examining what this warning letter may reveal about FDA’s evolving QMSR inspection approach.
Thanks for reading Let's Talk Risk!. If you liked this post, share with others.

Note:
The audio summary was prepared using Google NotebookLM, an AI-enabled research tool. Here are a few key resources used for this analysis:
* FDA (2026, May 27). Linemaster Switch Corporation, Warning Letter (CMS 730215), FDA
* FDA (2025, November 11). Envoy Medical Inc., Warning Letter (CMS 718762), FDA
* FDA (2026, April 30). ZOLL Medical Corporation, Warning Letter (CMS 711320), FDA.
* FDA (2026, February 26). Longhorn Vaccines and Diagnostics LLC, Warning Letter (CMS 721702), FDA.


This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe